Featured Research Search Results

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

Clinicaltrials.gov identifier:
NCT05059444

Treatment
Post-treatment study to monitor for recurrence

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

Clinicaltrials.gov identifier:
NCT07218809

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T

Clinicaltrials.gov identifier:
NCT06878248

Treatment
Phase 1 treatment study for people with advanced solid tumors

Comparing an Experimental Drug Puxi-Sam with Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)

Clinicaltrials.gov identifier:
NCT07044336

Treatment
Phase 3 treatment study for metastatic endometrial cancer

Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab

Clinicaltrials.gov identifier:
NCT05112601

Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker

Study of a New Drug, E7386, in Combination with Lenvatinib in People with Previously Treated Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04008797

Treatment
Treatment study for people with previously treated endometrial cancer

Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

Clinicaltrials.gov identifier:
NCT05372640

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT06841354

Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

Clinicaltrials.gov identifier:
NCT06545942

Treatment
Treatment study for people with advanced or metastatic cancers

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Post-surgery Immunotherapy (Toripalimab) for MMR-D / MSI-H Stage IIB-III Colon Cancer

Clinicaltrials.gov identifier:
NCT07140679

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT06958328

Treatment
Radiation treatment study for people with locally advanced pancreatic cancer

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer

Clinicaltrials.gov identifier:
NCT06952803

Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation